Extrahepatic targeting of lipid nanoparticles in vivo with intracellular targeting for future nanomedicines

• Published in: Advanced drug delivery reviews Vol. 188; p. 114417
• Main Authors: Nakamura, Takashi, Sato, Yusuke, Yamada, Yuma, Abd Elwakil, Mahmoud M., Kimura, Seigo, Younis, Mahmoud A., Harashima, Hideyoshi
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.09.2022
• Subjects: Drug Delivery Systems - methods; Humans; Lipid nanoparticle; Liposomes; Liver targeting; Lung targeting; Lymph targeting; Mitochondria; Nanomedicine; Nanoparticles; Nucleic acid; Nucleic Acids; Spleen targeting; Tumor targeting; Mitochondria; Tumor targeting; Lung targeting; Spleen targeting; Liver targeting; Lymph targeting; Lipid nanoparticle; Nucleic acid
• ISSN: 0169-409X; 1872-8294
• DOI: 10.1016/j.addr.2022.114417

[Display omitted] A new era of nanomedicines that involve nucleic acids/gene therapy has been opened after two decades in 21st century and new types of more efficient drug delivery systems (DDS) are highly expected and will include extrahepatic delivery. In this review, we summarize the possibility and expectations for the extrahepatic delivery of small interfering RNA/messenger RNA/plasmid DNA/genome editing to the spleen, lung, tumor, lymph nodes as well as the liver based on our studies as well as reported information. Passive targeting and active targeting are discussed in in vivo delivery and the importance of controlled intracellular trafficking for successful therapeutic results are also discussed. In addition, mitochondrial delivery as a novel strategy for nucleic acids/gene therapy is introduced to expand the therapeutic dimension of nucleic acids/gene therapy in the liver as well as the heart, kidney and brain.